Jean Jacques Bienaime
CIK 1221590 · Chief Executive Officer · last filed 2026-09-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BMRN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PALO ALTO, CA 94304
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ASND | Director | 2,000 | $245.15 | $490.3K | $699.3K | 4 | 2026-09-28 |
| KROS | Director | 19,592 | $11.33 | $222.0K | $75.8K | 9 | 2026-08-19 |
| IMNM | Director | 38,915 | $17.89 | $696.2K | $437.4K | 12 | 2026-06-12 |
| INCY | Director | 24,424 | $113.31 | $2.77M | $320.5K | 45 | 2026-06-10 |
| BMRN | Director | 473,892 | $55.75 | $26.42M | -$241.37M | 336 | 2024-05-21 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 1,706 | — | — | $3.9K | 4 | 2014-03-10 |
Recent Filings · Page 2 of 47
465 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-28 | INCY | Mixed | +1,941 | -$79 | EDGAR |
| 2026-05-27 | ASND | Buy (P) | +400 | $95.1K | EDGAR |
| 2026-05-19 | KROS | Buy (P) | +1,000 | $10.6K | EDGAR |
| 2026-05-19 | IMNM | Buy (P) | +5,000 | $103.5K | EDGAR |
| 2026-04-17 | KROS | Buy (P) | +1,000 | $11.7K | EDGAR |
| 2026-03-12 | IMNM | Buy (P) | +2,000 | $43.7K | EDGAR |
| 2026-03-11 | KROS | Buy (P) | +2,000 | $22.4K | EDGAR |
| 2025-06-12 | INCY | Grant (A) | +2,518 | $0 | EDGAR |
| 2025-06-12 | IMNM | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | KROS | Grant (A) | +5,250 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.